help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_2, 22-26, April 2008; doi:10.1634/theoncologist.13-S2-22
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toner, G. C.
Right arrow Articles by Hicks, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toner, G. C.
Right arrow Articles by Hicks, R. J.

PET for Sarcomas Other Than Gastrointestinal Stromal Tumors

Guy C. Tonera,c, Rodney J. Hicksb,c

aDivision of Haematology and Medical Oncology and bCentre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; cDepartment of Medicine, St Vincent's Medical School, University of Melbourne, Melbourne, Australia

Key Words. Sarcoma • PET scanning • Response assessment

Correspondence: Guy Toner, M.D., Peter MacCallum Cancer Institute, Medical Oncology, St. Andrews Place, East Melbourne, Australia 3002. Telephone: 613-9656-1111; Fax: 613-9656-1408; e-mail: guy.toner{at}petermac.org

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Positron emission tomography (PET) is increasingly used to diagnose, grade, and stage different types of tumors and to assess tumor response to therapy. Metabolic data acquired by fluorine-18-fluorodeoxyglucose (18FDG)-PET may facilitate accurate grading of sarcomas and have prognostic value when combined with other grading methods and various clinical/radiological features. In addition, 18FDG-PET is currently being evaluated in several cancer types for its utility in biopsy guidance. Whole-body 18FDG-PET also appears to be superior to other imaging modalities in detecting bone metastases in certain sarcoma patients. New PET tracers currently being investigated include 18F-fluorothymidine (18F-FLT) and 18F-misonidazole. 18F-FLT can help to determine tumor growth, rather than tumor shrinkage, which could be used to evaluate treatment response in sarcomas. PET imaging offers invaluable information to help maximize the clinical benefit of patients with sarcoma. This article reviews the use of PET in sarcoma management and its potential applications in the near future.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.